Akari Therapeutics, Plc AKTX
NASDAQ
Recommendation
Dividend Power Score
Day's Range
$7.94$8.64
Latest Close
Volume
--
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
EPS (TTM)
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -11.20% | -10.02% | -13.34% | -0.53% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.96% | -19.89% | -31.63% | -28.79% | -- |
| Operating Income | -6.96% | 19.89% | 31.63% | 28.79% | -- |
| Income Before Tax | -167.56% | -66.82% | 7.53% | 16.36% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -152.38% | -56.43% | 12.60% | 21.75% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -152.38% | -56.43% | 12.60% | 21.75% | -- |
| EBIT | -6.96% | 19.89% | 31.63% | 28.79% | -- |
| EBITDA | 57.41% | 43.77% | 31.66% | 28.80% | -- |
| EPS Basic | -0.22% | 54.58% | 75.04% | 79.12% | -- |
| Normalized Basic EPS | 60.02% | 76.52% | 81.21% | 82.36% | -- |
| EPS Diluted | -0.22% | 54.58% | 75.04% | 79.12% | -- |
| Normalized Diluted EPS | 60.02% | 76.52% | 81.21% | 82.36% | -- |
| Average Basic Shares Outstanding | 128.96% | 144.04% | 181.97% | 238.55% | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |